Abstract
Motor complications (dyskinesias and motor fluctuations) are a common and disabling problem of dopaminergic therapy in Parkinson’s disease, which are often difficult to treat with the current therapeutic strategies. It has been proposed that continuous dopaminergic delivery could reduce the emergence of motor complications, which has been tried with levodopa intestinal infusion or subcutaneous apomorphine infusion. In selected refractory cases, surgical approaches such as deep brain stimulation should be considered. Ongoing clinical and preclinical research tried to lead the field into the discovery of other therapeutic targets and strategies that might prevent or reduce motor complications. These include drugs targeting non-dopaminergic systems (e.g. glutamatergic, serotonergic, noradrenergic, adenosinergic and cholinergic systems), gene therapy for delivering neurotrophic factors or critical enzymes for dopamine synthesis, and cell therapy. These studies found variable results, some of them promising, with the possibility of new therapeutic armamentarium in the management of Parkinson’s disease in the near future.
Keywords: Levodopa, motor complications, motor fluctuations, Parkinson disease, peak-dose dyskinesia.
CNS & Neurological Disorders - Drug Targets
Title:Motor Complications in Parkinson’s Disease: A Comprehensive Review of Emergent Management Strategies
Volume: 12 Issue: 7
Author(s): Susana Marques de Sousa and João Massano
Affiliation:
Keywords: Levodopa, motor complications, motor fluctuations, Parkinson disease, peak-dose dyskinesia.
Abstract: Motor complications (dyskinesias and motor fluctuations) are a common and disabling problem of dopaminergic therapy in Parkinson’s disease, which are often difficult to treat with the current therapeutic strategies. It has been proposed that continuous dopaminergic delivery could reduce the emergence of motor complications, which has been tried with levodopa intestinal infusion or subcutaneous apomorphine infusion. In selected refractory cases, surgical approaches such as deep brain stimulation should be considered. Ongoing clinical and preclinical research tried to lead the field into the discovery of other therapeutic targets and strategies that might prevent or reduce motor complications. These include drugs targeting non-dopaminergic systems (e.g. glutamatergic, serotonergic, noradrenergic, adenosinergic and cholinergic systems), gene therapy for delivering neurotrophic factors or critical enzymes for dopamine synthesis, and cell therapy. These studies found variable results, some of them promising, with the possibility of new therapeutic armamentarium in the management of Parkinson’s disease in the near future.
Export Options
About this article
Cite this article as:
Sousa Marques de Susana and Massano João, Motor Complications in Parkinson’s Disease: A Comprehensive Review of Emergent Management Strategies, CNS & Neurological Disorders - Drug Targets 2013; 12 (7) . https://dx.doi.org/10.2174/18715273113129990086
DOI https://dx.doi.org/10.2174/18715273113129990086 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics
Current Pharmaceutical Design Recent Advances in Progressive Supranuclear Palsy: A Review
Current Alzheimer Research A Review of Current Drug Targets and Pharmacology of Antipsychotic Treatment
Medicinal Chemistry Reviews - Online (Discontinued) Oestrogen-A Protective Factor in Schizophrenia?
Current Psychiatry Reviews Volumetric Changes in the Basal Ganglia After Antipsychotic Monotherapy: A Systematic Review
Current Medicinal Chemistry Relating Substructures and Side Effects of Drugs with Chemical-chemical Interactions
Combinatorial Chemistry & High Throughput Screening Antipsychotics in the Treatment of Impulsivity in Personality Disorders and Impulse Control Disorders
Current Psychopharmacology Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Cannabinoids: Between Neuroprotection and Neurotoxicity
Current Drug Targets - CNS & Neurological Disorders The Role of Neurogenesis in Neurodegenerative Diseases and its Implications for Therapeutic Development
CNS & Neurological Disorders - Drug Targets Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design Targeting the Progression of Parkinsons Disease
Current Neuropharmacology Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Synthesis of L-Dopa Modifier L-Dopa-L-His and its Interaction with DNA
Letters in Organic Chemistry Targeted D4 Dopamine Receptors: Implications for Drug Discovery and Therapeutic Development
Current Drug Targets Gene Therapy for Neurological Disorders: Challenges and Future Prospects for the Use of Growth Factors for the Treatment of Parkinsons Disease
Current Gene Therapy Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology Melatonin Redox Activity. Its Potential Clinical Applications in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry The Large Conductance Calcium- and Voltage-activated Potassium Channel (BK) and Epilepsy
CNS & Neurological Disorders - Drug Targets Regulation of Postsynaptic Stability by the L-type Calcium Channel Ca<sub>V</sub>1.3 and its Interaction with PDZ Proteins
Current Molecular Pharmacology